A blockbuster is born in J&J's Nucynta ER
This article was originally published in Scrip
Executive Summary
Johnson & Johnson has received FDA approval for Nucynta ER in moderate to severe chronic pain. Armed with clinical trial data showing comparable efficacy and superior tolerability to the market-leading opioid OxyContin, Nucynta ER is likely to be a commercial success for Johnson & Johnson. Additional benefits in neuropathic pain will further strengthen the clinical argument for its use.